Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs
| العنوان: | Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs |
|---|---|
| المؤلفون: | Sarah C. Gilbert, Scott Bruce, Daniel C. Smith, Sarah Davies, Carina Citra Dewi Joe, Adam Berg, Adam J. Ritchie, Daniel Pappas, Yuanyuan Li, Piergiuseppe Nestola, Maria Kapanidou, Amar Joshi, Paul Cashen, Gaurav Gupta, Raghavan Venkat, Alexander D. Douglas, Lee Davies, David O. Mainwaring, Mark Woodyer, Richard Turner, Daan Bormans, Jonathan Humphreys, Sofiya Fedosyuk, Catherine M. Green, Nick Smith, Dennis Verbart, Nitin Chopra, Nicole Bleckwenn, Teresa Lambe, Jinlin Jiang, Rameswara R Segireddy, Thomas Linke, Lisa Cooper, Byron Rees, Carol Knevelman |
| المصدر: | Biotechnology and Bioengineering |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Drug Industry, Pan troglodytes, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Chimpanzee adenovirus, Bioengineering, Animal Cell Biotechnology, Applied Microbiology and Biotechnology, Article, ARTICLES, vaccine, ChAdOx1 nCoV-19, Pandemic, Vaccine Development, Process economics, Escherichia coli, Animals, Humans, Technology, Pharmaceutical, Distributed manufacturing, Geography, SARS-CoV-2, Vaccination, COVID-19, Limiting, adenovirus, HEK293 Cells, Risk analysis (engineering), Business, distributed manufacturing, Biotechnology |
| الوصف: | Manufacturing has been the key factor limiting rollout of vaccination during the COVID‐19 pandemic, requiring rapid development and large‐scale implementation of novel manufacturing technologies. ChAdOx1 nCoV‐19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS‐CoV‐2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large‐scale production. We discuss the process economics and the “distributed manufacturing” approach we have taken to provide the vaccine at globally‐relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID‐19 vaccine supply at low cost. Well over a billion doses of the ChAdOx1 nCoV‐19 vaccine developed by The University of Oxford and AstraZeneca have been produced and distributed at low cost. This represents a substantial proportion of global COVID‐19 vaccine supply to date, especially in low‐ and middle‐income countries. The authors report on the development of the manufacturing process for the vaccine, and the process economics and distributed manufacturing approach involving bulk vaccine (drug substance) production on five continents. |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78020b799701a9645d14a6b2ea46dd38 https://ora.ox.ac.uk/objects/uuid:9aab02ba-dac8-40f5-979a-f773c0fbf98d |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....78020b799701a9645d14a6b2ea46dd38 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |